Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Ono's Revenue and Profits Soar as Opdivo Sales Jump 1,714%
Ono Pharmaceutical saw a 67.5% increase in its group sales in April-September buoyed by strong sales of the anti-PD-1 antibody Opdivo (nivolumab), the company said on November 7. In the first half of FY2016 ending March, the company posted group…
To read the full story
Related Article
- Opdivo Drives Ono to Record Profits in FY2016
May 15, 2017
- Ono’s Opdivo Sales at 82.6 Billion Yen in April-December
February 3, 2017
- Current Drug Pricing System Became Unfit for New Drugs Like Opdivo: Ono Chief
November 8, 2016
BUSINESS
- Meiji Opposes French Fund’s Push to Review Pharma Spin-Off
May 15, 2026
- FRONTEO Opens AI Drug Discovery Lab, Pivots to Out-Licensing Model
May 15, 2026
- Inqovi-Venetoclax Combo Wins FDA Approval in AML: Taiho
May 15, 2026
- Chugai Files Gazyva for Idiopathic Nephrotic Syndrome in Japan
May 15, 2026
- Astellas, MSD File Padcev-Keytruda for Cisplatin-Eligible MIBC in Japan
May 15, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…